SECTIONS

Pacific Edge

BusinessMay 26

Pacific Edge praised

Pacific Edge should be applauded for its international success and its ongoing commitment to Dunedin, Otago Chamber of Commerce chief executive John Christie said yesterday.
BusinessMarch 14

Pacific Edge in top 50

Dunedin cancer diagnostic company Pacific Edge has edged high street clothing retailer Hallenstein Glasson out of the stock exchange's NZX top 50 index.
BusinessMarch 2

Pacific Edge wins grants

Dunedin-based cancer diagnostic company Pacific Edge is to receive $4.5 million in government grants towards research and development over the next three years.
Pacific Edge wins grants
Pacific Edge wins grants
BusinessDecember 27

Pacific Edge in business

Following a stellar year hitting targets and milestones, listed Dunedin bio-tech company Pacific Edge has been named Otago Daily Times Business of The Year 2013. Business reporter Simon Hartley profiles Pacific Edge's decade of persistence.
Pacific Edge in business
Pacific Edge in business
BusinessNovember 29

Loss, new products

Pacific Edge cancer diagnostic company has as expected posted a half-year trading loss, of $4.97 million yesterday, having the day previously clinched almost $29 million in additional funding from its shareholders.
BusinessOctober 25

Pacific Edge becomes a market superstar

Cancer diagnostic company Pacific Edge became a Dunedin-based superstar this week as its share price briefly reached $1.75 on the back of several good news announcements.
Pacific Edge becomes a market superstar
Pacific Edge becomes a market superstar
BusinessOctober 23

Pacific Edge shares volatile

The recent volatility in Pacific Edge's share price was surreal, chief executive David Darling said yesterday.
Pacific Edge shares volatile
Pacific Edge shares volatile
BusinessOctober 16

Major US client for Pacific Edge

A massive share spike followed Dunedin-based cancer diagnostic company Pacific Edge announcing it is signing up a key US client, FedMed, a national health network servicing 40 million Americans.
Major US client for Pacific Edge
Major US client for Pacific Edge
BusinessMarch 18

Pacific Edge approved to begin operating US lab

Crucial regulatory approval has been gained in the United States by listed Dunedin cancer-diagnostic company Pacific Edge, which will allow it to begin operating its $4.5 million laboratory in Pennsylvania.
BusinessMarch 12

Pacific Edge hits all time high

Shares in Dunedin-based cancer diagnostic company Pacific Edge briefly hit an all time high of 79c yesterday, following the appointment of a non-executive director to its US subsidiary.
Pacific Edge hits all time high
Pacific Edge hits all time high
BusinessNovember 30

Set-up, development costs make loss for Pacific Edge

Dunedin bio-tech company Pacific Edge has reported an expected loss of $3.24 million for the half year as it awaits US regulatory approval to open its just completed $4.5 million laboratory in Pennsylvania.
Set-up, development costs make loss for Pacific Edge
Set-up, development costs make loss for Pacific Edge
BusinessAugust 23

Pacific Edge ready for US roll-out

The past 12 months have been a thrilling ride for Pacific Edge, but chief executive David Darling said yesterday that more excitement was on the way for the company and its shareholders.
Pacific Edge ready for US roll-out
Pacific Edge ready for US roll-out
BusinessJuly 2

Upbeat but Pacific Edge haemorrhages cash

Pacific Edge continues to haemorrhage cash as it seeks to establish itself as a world leader in bladder cancer diagnosis, but the company remains upbeat about its prospects for the coming year.
DunedinJune 19

Singapore patent for Dunedin company's cancer test

Dunedin-based Pacific Edge says it has been awarded a patent in Singapore for its colorectal cancer prognostic technology, and anticipates the patent will be issued in other targeted countries in the next 12 to 24 months.
Singapore patent for Dunedin company's cancer test
Singapore patent for Dunedin company's cancer test
BusinessMarch 27

Northern contract for bladder test

Dunedin-based biotech company Pacific Edge has announced another contract for its expanding diagnostic bladder cancer test, which appears to be going from strength to strength.
Northern contract for bladder test
Northern contract for bladder test
BusinessFebruary 1

NZ biotech setting up US lab, HQ

Dunedin-based biotech company Pacific Edge is setting up its United States commercial laboratory and headquarters for its diagnostic bladder cancer test in Pennsylvania, within the Hershey Centre for Applied Research, a university and technology research facility.
NZ biotech setting up US lab, HQ
NZ biotech setting up US lab, HQ
BusinessDecember 23

Diagnostic concern targets US market

Dunedin-based cancer diagnostic company Pacific Edge has posted a half-year loss of $1.7 million, mainly through costs associated with undertaking clinical trials and further product development.
Diagnostic concern targets US market
Diagnostic concern targets US market
BusinessSeptember 5

Pacific Edge funds for US expansion grow to $15 million

Dunedin-based cancer diagnostic company Pacific Edge has raised 95% - or $15 million of $16 million sought - to swell its United States expansion coffers to $20.1 million.
BusinessAugust 26

US key goal for Pacific Edge

Pacific Edge shareholders can expect to see the Dunedin-based company concentrate on getting its cancer diagnostic products into the United States, backed by potentially more than $20 million in new funding.
US key goal for Pacific Edge
US key goal for Pacific Edge
BusinessMarch 28

Pacific Edge optimistic of new markets

Biotech company Pacific Edge, of Dunedin, is confident of securing several licence agreements this year for its mainstay bladder cancer detection test - in development now for more than seven years.
Pacific Edge optimistic of new markets
Pacific Edge optimistic of new markets
BusinessNovember 29

Cancer test trial results positive

The accounts of medical diagnostic company Pacific Edge remain in the red but chairman Chris Swann said it was on the verge of a commercial breakthrough.